Vaccinex Announces Creation of Eight New Antibody Discovery Agreements
Vaccinex, a biotechnology company specializing in Alzheimer’s disease and cancer treatments, has announced the creation of eight new antibody discovery agreements. These agreements will utilize Vaccinex’s proprietary ActivMAb platform, which allows for the selection of antibodies against challenging transmembrane protein targets.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
